The Three-Decade Long Journey in Heart Failure Drug Development
Heart failure is a global disease with increasing prevalence due to an aging worldwide population with increasing co-morbidities. Despite several therapeutic options available to treat HFrEF, morbidity and mortality remain high. Importantly, no approved therapies are available to treat HFpEF. This p...
Saved in:
Published in | Handbook of experimental pharmacology Vol. 243; pp. 1 - 14 |
---|---|
Main Authors | , , , |
Format | Book Chapter Journal Article |
Language | English |
Published |
Switzerland
Springer International Publishing AG
01.01.2017
Springer International Publishing |
Series | Handbook of Experimental Pharmacology |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Heart failure is a global disease with increasing prevalence due to an aging worldwide population with increasing co-morbidities. Despite several therapeutic options available to treat HFrEF, morbidity and mortality remain high. Importantly, no approved therapies are available to treat HFpEF. This paper will briefly summarize the burden of disease, HF classification and definitions and the landmark clinical trials in both HFrEF and HFpEF. Given the increasing incidence and prevalence of HF and the high morbidity and mortality associated with this disease, continued development efforts are essential to address the unmet needs of these patients. |
---|---|
ISBN: | 3319596586 9783319596587 |
ISSN: | 0171-2004 1865-0325 |
DOI: | 10.1007/164_2016_101 |